July 24, 2014
The Pharmaceuticals and Medical Devices Agency (PMDA) said on July 18 that Mitsubishi Tanabe’s anti-human TNFα monoclonal antibody Remicade (recombinant infliximab) and its biosimilars have come under review for the potential risk of rhabdomyolysis. Certain safety measures such the revision...read more